AJ Lanigan: Yes. The Truth is, pharma companies are generating huge income with therapies like Keytruda and Opdivo that deal with PD-1 and PD-L1. Listed here’s the super cool part: think about checkpoints as targeted visitors alerts. You don’t want an immune technique that’s running wild similar to a freight waiting for link from Social Bookmarking (3)